Galera Therapeutics (GRTX) AI Stock Analysis

• Market Cap: $1.79M
• Dividend Yield: N/A
• Average Volume (3M): 51.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.26
• Revenue Growth: N/A
• EPS Growth: 75.56%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 75,462,390
• 10 Day Avg. Volume: 43,905
• 30 Day Avg. Volume: 51,227
• PEG Ratio: 0.02
• Price to Book (P/B): -0.37
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.93
• Enterprise Value/Market Cap: 20.17
• Enterprise Value/Revenue: 205.32
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.44
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 22 Underperform
• Price Target: ―

Galera Therapeutics exhibits significant financial instability with consistent losses and negative equity, heavily impacting its overall score. The technical analysis indicates bearish market momentum, and the valuation is unattractive with a negative P/E ratio. The absence of positive earnings call data or corporate events further contributes to the poor stock performance outlook.

Galera Therapeutics Business Overview & Revenue Model

Company Description

Galera Therapeutics, Inc. (GRTX) is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel therapeutics targeting oxygen metabolic pathways. The company is primarily engaged in the development of small molecule therapies that have the potential to transform radiotherapy and chemotherapy by reducing their toxicities, thereby enhancing patient outcomes. Its lead product candidate, avasopasem manganese, is aimed at treating severe oral mucositis (SOM) in patients undergoing radiotherapy for head and neck cancer.

How the Company Makes Money

Galera Therapeutics primarily makes money through the development and commercialization of its drug candidates. As a clinical-stage company, its revenue model is largely centered on successful clinical trials leading to regulatory approvals and subsequent commercialization of its products. Revenue streams may include milestone payments, licensing agreements, and potentially sales revenue once its therapeutics receive regulatory approval. Additionally, Galera may engage in strategic partnerships with larger pharmaceutical companies to enhance the development and distribution of its therapies, which could also contribute to its financial earnings.

Galera Therapeutics Financial Statement Overview

Summary

Galera Therapeutics is facing significant financial difficulties, with no revenue generation and continuous losses. The negative equity and reliance on financing indicate financial instability and potential risks of insolvency without strategic changes or new funding.

Income Statement

Galera Therapeutics has shown consistent losses with no revenue generated over the years, resulting in negative gross margins and net profit margins. The continuous high EBIT and net losses indicate significant challenges in achieving profitability.

Balance Sheet

The company has a negative stockholders' equity, indicating liabilities exceed assets, which poses a significant risk. The absence of debt is a positive aspect, but the negative equity ratio and large accumulated deficits overshadow this.

Cash Flow

Galera Therapeutics has experienced negative free cash flow consistently, reflecting the ongoing cash burn without offsetting cash inflows. The company relies heavily on financing activities to sustain operations, which is unsustainable long-term.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-3.84M	-259.00K	-114.00K	-778.00K	-368.00K
	EBIT
-17.55M	-20.16M	-46.95M	-51.23M	-73.37M	-70.55M
	EBITDA
-16.86M	-20.16M	-46.69M	-50.61M	-72.56M	-69.01M
	Net Income Common Stockholders
-16.17M	-18.96M	-59.08M	-62.22M	-87.73M	-74.22M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.69M	8.29M	18.26M	31.60M	71.22M	72.78M
	Total Assets
7.66M	10.10M	26.14M	44.04M	83.31M	84.10M
	Total Debt
0.00	0.00	1.25M	44.00K	302.00K	534.00K
	Net Debt
-6.69M	-8.29M	-17.01M	-4.22M	-19.56M	-15.34M
	Total Liabilities
152.02M	153.77M	157.33M	153.22M	141.31M	77.98M
	Stockholders Equity
-144.36M	-143.67M	-131.19M	-109.18M	-58.00M	6.12M
Cash Flow		Free Cash Flow
2.45M	-12.14M	-44.91M	-43.45M	-68.24M	-59.99M
	Operating Cash Flow
2.45M	-12.14M	-44.85M	-43.43M	-67.96M	-59.54M
	Investing Cash Flow
-46.00K	-46.00K	27.29M	23.99M	5.24M	36.55M
	Financing Cash Flow
2.86M	2.22M	31.50M	3.89M	66.71M	20.51M

Galera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRTX, the sentiment is Neutral. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.04, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 85.33 is Negative, neither overbought nor oversold. The STOCH value of -8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GRTX.

Galera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
SCNI	52 Neutral	$2.18M	0.41	138.38%	―	―	―
INM	44 Neutral	$3.34M	―	-91.71%	―	-11.94%	56.72%
EYEN	38 Underperform	$11.76M	―	-388.03%	―	1414.02%	-14.78%
SHPH	32 Underperform	$2.44M	―	-346.19%	―	―	-7.18%
REVB	28 Underperform	$1.38M	―	-233.26%	―	―	-115.81%
GRTX	22 Underperform	$1.79M	―	13.71%	―	―	75.56%

Galera Therapeutics Corporate Events

Galera Therapeutics Expands with Nova Pharmaceuticals Acquisition

Galera Therapeutics has completed the acquisition of Nova Pharmaceuticals, which focuses on developing a pan-NOS inhibitor to treat resistant forms of breast cancer. The merger shifts Galera’s strategy towards anti-cancer therapeutics, with plans for multiple clinical trials, including a Phase 1/2 trial for metaplastic breast cancer. This acquisition is expected to bolster Galera’s financial and operational capabilities, with support from investors and strategic partnerships to fund developments through 2026.